<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506530</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/14/7425</org_study_id>
    <nct_id>NCT02506530</nct_id>
  </id_info>
  <brief_title>Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema</brief_title>
  <acronym>ELOCS</acronym>
  <official_title>Contribution of an Endermologie LPG Cellu M6 Treatment in the Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LPG SYSTEMS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the benefit of LPG Cellu M6 in addition of intensive decongestive&#xD;
      treatment in reducing secondary lymphoedema in breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to assess the proportion of successfully treated patients&#xD;
      (success rate).&#xD;
&#xD;
      That is to say patients having a reduction of excess arm volume ≥ 30% after 5 days of three&#xD;
      types of treatment for secondary lymphoedema :&#xD;
&#xD;
      Group 1: standard intensive decongestive therapy for 5 days (bandages + manual lymphatic&#xD;
      drainage).&#xD;
&#xD;
      Group 2: standard intensive decongestive therapy (bandages + manual lymphatic drainage) +&#xD;
      Cellu M6 for 5 days Group 3: Bandages + Cellu M6 for 5 days&#xD;
&#xD;
      Symptomatic treatment of lymphoedema reference is intensive decongestive therapy including&#xD;
      manual lymphatic drainage, compression of multicomponent bandaging, therapeutic exercise and&#xD;
      skin care (HAS 2012 ISL International Society of Lymphology, 2013).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients successfully treated (reduction of the excessive volume in the arm&gt;30%)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of the excessive volume in the arm since hospitalization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess adverse effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>cost effectiveness analysis of treatments</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>intensive decongestive treatment (IDT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an intensive decongestive treatment for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDT + Cellu M6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellu M6 + bandages</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an bandages + Cellu M6 for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intensive decongestive treatment</intervention_name>
    <description>intensive decongestive treatment</description>
    <arm_group_label>IDT + Cellu M6</arm_group_label>
    <arm_group_label>intensive decongestive treatment (IDT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellu M6</intervention_name>
    <description>Use of Cellu M6</description>
    <arm_group_label>Cellu M6 + bandages</arm_group_label>
    <arm_group_label>IDT + Cellu M6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from a lymphoedema consequence of a breast cancer of grades 2 or 3&#xD;
             (ISL)&#xD;
&#xD;
          -  Patients suffering from Lymphoedema for 6 months or more&#xD;
&#xD;
          -  Patients with a difference between arms &gt;10%&#xD;
&#xD;
          -  Patients who had ever had an axillary node dissection&#xD;
&#xD;
          -  Patients hospitalized for intensive standard treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary lymphoedema&#xD;
&#xD;
          -  Venous insufficiency of the upper members&#xD;
&#xD;
          -  severe arterial obstruction&#xD;
&#xD;
          -  obliterating arteritis of the upper limbs&#xD;
&#xD;
          -  Bilateral lymphoedema&#xD;
&#xD;
          -  Breast cancer recurrence&#xD;
&#xD;
          -  Another cancer in treatment&#xD;
&#xD;
          -  Decompensated heart failure&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  acute infection&#xD;
&#xD;
          -  Deep venous thrombosis&#xD;
&#xD;
          -  Skin atrophy of the upper member&#xD;
&#xD;
          -  Bullous dermatosis&#xD;
&#xD;
          -  Acute dermatitis with epidermitis or dermatitis-hypodermitis&#xD;
&#xD;
          -  Infected wound&#xD;
&#xD;
          -  Inflammatory scar or consequence of a recent surgery (&lt;1 month)&#xD;
&#xD;
          -  Presence of osteosynthesis equipment under the skin with an external part in the upper&#xD;
             member to treat&#xD;
&#xD;
          -  Hyperalgesia of the shoulder&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie MALLOIZEL-DELAUNAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MALLOIZEL DELAUNAY Julie</name>
      <address>
        <city>Toulouse</city>
        <state>Midi Pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009 Jan-Feb;59(1):8-24. doi: 10.3322/caac.20001. Review.</citation>
    <PMID>19147865</PMID>
  </reference>
  <reference>
    <citation>Kärki A, Anttila H, Tasmuth T, Rautakorpi UM. Lymphoedema therapy in breast cancer patients: a systematic review on effectiveness and a survey of current practices and costs in Finland. Acta Oncol. 2009;48(6):850-9. doi: 10.1080/02841860902755251. Review.</citation>
    <PMID>19235573</PMID>
  </reference>
  <reference>
    <citation>Mayrovitz HN. The standard of care for lymphedema: current concepts and physiological considerations. Lymphat Res Biol. 2009;7(2):101-8. doi: 10.1089/lrb.2009.0006.</citation>
    <PMID>19522678</PMID>
  </reference>
  <reference>
    <citation>Vignes S, Porcher R, Arrault M, Dupuy A. Long-term management of breast cancer-related lymphedema after intensive decongestive physiotherapy. Breast Cancer Res Treat. 2007 Mar;101(3):285-90. Epub 2006 Jul 7.</citation>
    <PMID>16826318</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphedema</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

